摘要
目的探讨卡维地洛对糖尿病心肌病患者血清瘦素水平及左心室功能的影响。方法选择40例新诊断的糖尿病心肌病伴心功能不全患者，随机分为两组，对照组给予常规治疗，卡维地洛组（治疗组）在常规治疗基础上加用卡维地洛口服。于治疗前及治疗6个月后检测血清瘦素和胰岛素水平，及心脏超声检查。结果卡维地洛组治疗后的瘦素水平及胰岛素抵抗指数分别为（7．18±2．06）μg/L、（2．92±0．62），较治疗前下降（P〈0．05），而对照组治疗前后差异无统计学意义（P〉0．05）。治疗后卡维地洛组LVEF、E／A比值[分别为（46．9±6．8）％、（1．05±0．07）]增加，LVMI、LVEDd[分别为（108±6）g/m2、（51．8±5．7）mm]下降，与治疗前比较以及与对照组治疗后比较，差异均有统计学意义（均P〈0．05）。结论卡维地洛能降低糖尿病心肌病患者血清瘦素水平，改善胰岛素抵抗及左心室功能。
Objective To evaluate the effects of carvedilol on the cardiac function and serum leptin lever in the treatment of diabetic cardiomyopathy. Methods 40 patients with diabetic cardiomyopathy were randomly divided into carvedilol group and control group. Two groups were given normal therapy and the carvedilol group added carvedilol. The serum levels of leptin and insulin and the heart ultrasound check were measured before and after six months of therapy. Results After therapy the serum levels of leptin and insulin resistance index [ （7. 18 ± 2.06）μg/L, （ 2.92 ± 0.62 ） ] were blower than that before therapy in carvedilol group but not control group. After therapy the value of LVEF and E/A were higher[ （46.9± 6.8） %, （ 1.05 ±0.07） ] and LVMI and LVEDd were lower[ （ 108 ± 6） g/ m2, （51.8 ± 5.7 ）mm] than that before therapy in carvedilol group but not control group（ all P 〈 0.05 ）. Conclusion Carvedilol could decrease the levels of serum leptin in patient with diabetic cardiomyopathy and improve insulin resistance and left entricular function.
出处
《中国基层医药》
CAS
2012年第17期2571-2572,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
心肌肌病
糖尿病
卡维地洛
瘦素
心室功能
左
胰岛素抵抗
Cardiomyopathies
Diabetes mellitus
Carvedilol
Leptin
Ventricular function, left
Insulin resist-ance
